autoimmune diseases

News

J&J gets EU approval for Imaavy in gMG

J&J's Imaavy has become the first FcRn blocker to be approved in the EU for both adolescent and adult patients with generalised myasthenia gravis.

News

BMS builds in 'in vivo' cell therapy with $1.5bn Orbital buy

Bristol Myers Squibb has ended the week with an agreement to buy Orbital Therapeutics, a developer of in vivo cell therapies, for $1.5bn in cash.

News

Mary Brunkow, Fred Ramsdell, and Shimon Sakaguchi

Regulatory T-cell scientist trio wins Nobel Prize

The Nobel Prize in Physiology or Medicine goes to three scientists for their work on regulatory T-cells, spawning hundreds of trials of new therapies.

News

More good news in Sjogren's as RemeGen trial delivers

A second new drug, RemeGen's telitacicept, has shown efficacy in a phase 3 Sjögren's syndrome trial in the space of a week.

News

Novartis two for two as ianalumab scores again

Novartis' ianalumab has delivered another win in primary immune thrombocytopenia, its second win in autoimmune diseases in 24 hours.

News

AbbVie cuts $1.9bn+ deal with IGI for trispecific antibody

AbbVie has signed another deal in its effort to build an industry-leading position in multispecific antibodies for blood cancers.

J&J gets EU approval for Imaavy in gMG

BMS builds in 'in vivo' cell therapy with $1.5bn Orbital buy

Regulatory T-cell scientist trio wins Nobel Prize

More good news in Sjogren's as RemeGen trial delivers

Novartis two for two as ianalumab scores again

AbbVie cuts $1.9bn+ deal with IGI for trispecific antibody

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

autoimmune diseases

Editor's Picks